Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
MarketWatch.com - Top Stories, MarketWatch
Wed, 06/16/2021 - 2:10pm
Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.